September 9, 2019Open Access

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

Key Points

Key points are not available for this paper at this time.

Abstract

The analysis of TFS between ICI cessation and subsequent therapy initiation revealed longer TFS without toxicity for patients with advanced melanoma who received nivolumab plus ipilimumab compared with nivolumab or ipilimumab. Regardless of treatment, a small proportion of the TFS involved grade 3 or higher TRAEs.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Meredith M. Regan

Lillian Werner

Sumati Rao

Journals

Journal of Clinical Oncology

Actions

Institutions

Harvard University

Cornell University

Yale University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study